Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Biofactors. 2022 Sep;48(5):1005-1026. doi: 10.1002/biof.1891. Epub 2022 Sep 29.
After the initiation of inflammation, a series of processes start to resolve the inflammation. A group of endogenous lipid mediators, namely specialized pro-resolving lipid mediators is at the top list of inflammation resolution. Resolvin D1 (RvD1), is one of the lipid mediators with significant anti-inflammatory properties. It is produced from docosahexaenoic acid (omega-3 polyunsaturated fatty acid) in the body. In this article, we aimed to review the most recent findings concerning the pharmacological effects of RvD1 in the central nervous system with a focus on major neurological diseases and dysfunctions. A literature review of the past studies demonstrated that RvD1 plasma level changes during mania, depression, and Parkinson's disease. Furthermore, RVD1 and its epimer, aspirin-triggered RvD1 (AT-RvD1), have significant therapeutic effects on experimental models of ischemic and traumatic brain injuries, memory dysfunction, pain, depression, amyotrophic lateral sclerosis, and Alzheimer's and Parkinson's diseases. Interestingly, the beneficial effects of RvD1 and AT-RvD1 were mostly induced at nanomolar and micromolar concentrations implying the significant potency of these lipid mediators in treating diseases with inflammation.
在炎症开始后，一系列的过程开始解决炎症。一组内源性脂质介质，即专门的促解决脂质介质，是炎症消退的首要名单。消退素 D1（RvD1）是具有显著抗炎特性的脂质介质之一。它是体内从二十二碳六烯酸（ω-3 多不饱和脂肪酸）产生的。在本文中，我们旨在综述 RvD1 在中枢神经系统中的药理学作用的最新发现，重点是主要的神经疾病和功能障碍。过去研究的文献回顾表明，RvD1 血浆水平在躁狂症、抑郁症和帕金森病期间发生变化。此外，RVD1 和其差向异构体，阿司匹林触发的 RvD1（AT-RvD1），对缺血性和创伤性脑损伤、记忆功能障碍、疼痛、抑郁、肌萎缩侧索硬化症以及阿尔茨海默病和帕金森病的实验模型具有显著的治疗作用。有趣的是，RvD1 和 AT-RvD1 的有益作用主要是在纳摩尔和微摩尔浓度下诱导的，这表明这些脂质介质在治疗炎症性疾病方面具有显著的效力。
